Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Job Trends

BioSpace 2026 Best Places to Work Spotlights Most Desirable Workplaces

BioSpace has named 50 life sciences companies to its 2026 Best Places to Work list. AbbVie, Amneal Pharmaceuticals and BridgeBio executives share what makes their organizations special.

November 4, 2025

7 min read

Angela Gabriel

FDA CDER director George Tidmarsh speaking in an FDA video

FDA

UPDATE: Tidmarsh Waffles on Resignation, Will Fight To Clear Name

Less than 24 hours after resigning his post as the FDA’s head drug regulator, George Tidmarsh is reportedly reconsidering his decision and vowing to fight for his name and credibility amid a probe into his “personal conduct” at the agency.

November 3, 2025

3 min read

Tristan Manalac

Business negotiation and cooperation vector concept. Symbol of a deal, handshake, success. Minimal design eps10 illustration.

Immunology and inflammation

Neurocrine Goes to China To Grow Pipeline in up to $881M TransThera Deal

At the center of the licensing deal is an NLRP3 inhibitor that has shown “encouraging efficacy in acute inflammation models,” according to TransThera, indicating its potential in various metabolic and inflammatory diseases.

November 3, 2025

1 min read

Dan Samorodnitsky

Brain shaped maze. Conceptual image of science and medicine. 3D illustration.

Neuroscience

Roche Piles $55M Into Blood-Brain Barrier Tech With Manifold

Manifold will use its tissue-targeting shuttle technology to help Roche develop new therapeutics for diseases of the central nervous system.

November 3, 2025

1 min read

Annalee Armstrong

IN PARTNERSHIP WITH ELEMENT

Pharma Faces Investor Woes and Tariff Threats, Turns to AI and Collaboration for Survival

Industry leaders say uncertainty in funding, clinical development and manufacturing is driving companies to embrace digital transformation, streamlined operations and strategic partnerships to navigate a turbulent market and global tariff pressures.

November 3, 2025

5 min read

BioSpace Insights

Pictured: uniQure headquarters in Amsterdam

Huntington’s disease

FDA Does ‘About-Face’ on UniQure’s Huntington’s Gene Therapy

A month after sparking optimism for patients with Huntington’s disease with highly positive data for AMT-130, uniQure revealed Monday that the FDA may be changing its tune on the evidence required for an approval application, a change of direction Stifel called “very challenging” for uniQure.

November 3, 2025

3 min read

Heather McKenzie

Legal battle lawsuit concept as two justice scales hitting each other as a justice court fight symbol representing a lawyer or attorney representation services with 3D illustration elements.

Mergers & acquisitions

UPDATE: Pfizer Files Lawsuits Against Novo Nordisk, Metsera To Stop Rival Bid

Pfizer has filed two separate lawsuits in an effort to stop Novo Nordisk’s unsolicited bid to acquire obesity biotech Metsera.

November 3, 2025

4 min read

Tristan Manalac

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS).

Gene editing

FDA Eyes Accelerated Reviews for Gene Editing Therapies

Vinay Prasad, chief of the FDA’s Center for Biologics Evaluation and Research, is planning to publish a paper this month to outline his office’s thinking on accelerating gene editing reviews.

November 3, 2025

2 min read

Tristan Manalac